Status:
UNKNOWN
High-flow Nasal Cannula Nebulization of Beta 2 Adrenergic Agonist During Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Lead Sponsor:
Poitiers University Hospital
Conditions:
Chronic Obstructive Pulmonary Disease
High-flow Nasal Cannula
Eligibility:
All Genders
18-100 years
Phase:
PHASE3
Brief Summary
High-flow nasal cannula is an oxygenation technique increasingly used for patients admitted for acute respiratory failure. Literature essentially concerns "de novo" acute hypoxemic failure and the int...
Eligibility Criteria
Inclusion
- Arterial pH over 7.25,
- Respiratory rate under 35 breaths/mn
- Glasgow Coma Scale equal to 15,
- indication of beta-2 agonist nebulization less than 8 per day (time between two nebulization more than 3 hours),
- NIV sessions spaced more than 6 hours.
Exclusion
- Urgent endotracheal intubation;
- Contraindication to beta 2 adrenergic agonist;
- Another organ failure (hemodynamic and neurological instability);
- Cardioselective beta-blocker during treatment of copd exacerbation;
Key Trial Info
Start Date :
January 11 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2020
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT03449056
Start Date
January 11 2019
End Date
April 1 2020
Last Update
February 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
C.H.U. de Poitiers
Poitiers, France, 86000